Targeted therapy in metastatic renal carcinoma

被引：41

作者：

Mattei, Jane ^{[1
]}

da Silva, Rodrigo Donalisio ^{[1
]}

Sehrt, David ^{[1
]}

Molina, Wilson R. ^{[1
]}

Kim, Fernando J. ^{[1
]}

机构：

[1] Denver Hlth Med Ctr, Denver, CO 80204 USA

来源：

CANCER LETTERS | 2014年 / 343卷 / 02期

关键词：

Target therapy; Renal cell carcinoma; Metastatic disease; Renal tumor; Adjuvant treatment; TYROSINE KINASE INHIBITORS; CELL CARCINOMA; INTERFERON-ALPHA; PHASE-II; SUNITINIB; BEVACIZUMAB; ERLOTINIB; AXITINIB; TEMSIROLIMUS; COMBINATION;

D O I：

10.1016/j.canlet.2013.09.038

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Advanced renal cell carcinoma is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. The development of new targeted therapy was result of understanding biological pathways underlying renal cell carcinoma. Our objective is to provide an overview of current therapies in metastatic renal cell carcinoma. Methods: MEDLINE/PUBMED was queried in December 2012 to identify abstracts, original and review articles. The research was conducted using the following words: "metastatic renal cell carcinoma" and "target therapy". Phase II and Phase III clinical trials were included followed FDA approval. Total of 40 studies were eligible for review. Conclusion: The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare. Published by Elsevier Ireland Ltd.

引用

页码：156 / 160

页数：5

共 40 条

[1] Everolimus for the treatment of advanced renal cell carcinoma [J].

Amato, Robert .

EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (07) :1143-1155

[2]

Berg WJ, 2000, SEMIN ONCOL, V27, P234

[3]

Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154

[4] Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma [J].

Bukowski, Ronald M. .

FRONTIERS IN ONCOLOGY, 2012, 2

[5]

Carmichael Courtney, 2012, Clin Adv Hematol Oncol, V10, P307

[6] Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: Results from a phase III randomized trial [J].

Cella, David ;

Li, Jim Z. ;

Cappelleri, Joseph C. ;

Bushmakin, Andrew ;

Charbonneau, Claudie ;

Kim, Sindy T. ;

Chen, Isan ;

Motzer, Robert J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3763-3769

[7] Future Directions in Renal Cell Carcinoma: 2011 and Beyond [J].

Cho, Daniel C. ;

Atkins, Michael B. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (04) :917-+

[8]

Dorff Tanya B, 2009, Ther Adv Med Oncol, V1, P183, DOI 10.1177/1758834009349119

[9] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[10] Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival [J].

Escudier, Bernard ;

Bellmunt, Joaquim ;

Negrier, Sylvie ;

Bajetta, Emilio ;

Melichar, Bohuslav ;

Bracarda, Sergio ;

Ravaud, Alain ;

Golding, Sophie ;

Jethwa, Sangeeta ;

Sneller, Vesna .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2144-2150

← 1 2 3 4 →